p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer (original) (raw)

References

• Bodner, SM, Minna, JD, Jensen, SM, D’Amico, D, Carbone, D, Mitsudomi, T, Fedorko, J, Buchhagen, DL, Nau, MM & Gazdar, AF (1992) Expression of mutant p53 proteins in lung cancer correlates with the loss of p53 gene mutation. Oncogene 7: 743–749
  CAS PubMed Google Scholar
• Bouvet, M, Ellis, LM, Nishizaki, M, Fijiwara, T, Tiu, W, Bucana, CD, Fang, B, Lee, JJ & Roth, J (1998) Adenovirus-mediated wild-type p53 gene transfer down regulates vascular endothelial growth factor expresion and inhibits angiogenesis in human colon cancer. Cancer Res 58: 2288–2292
  CAS Google Scholar
• Bristow, RE, Lagasse, LD & Karlan, BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 78: 2049–2062
  Article CAS Google Scholar
• Brown, R, Clugston, C, Burns, P, Edlin, A, Vasey, P, Kaye, SB & Vojtesek, B (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678–684
  Article CAS Google Scholar
• Buttitta, F, Marchetti, A, Gadducci, A, Pellegrini, S, Morganti, M, Carnicelli, V, Cosio, S, Gaggetti, O, Genazzani, AR & Bevilacqua, G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230–235
  Article CAS Google Scholar
• Cox, DR (1970). Analysis of Binary Data. Methuen: London
• Diebold, J, Baretton, G, Felchner, M, Meier, W, Dopfer, K, Schmidt, M & Lohrs, U (1996) Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341–349
  Article CAS Google Scholar
• Dong, Y, Walsh, MD, McGuckin, MA, Cummings, MC, Gabrielli, BG, Wright, GR, Hurst, T, Khoo, SK & Parsons, PG (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 74: 407–414
  Article CAS Google Scholar
• Eccles, DM, Brett, L, Lessels, A, Gruber, L, Lane, D, Steel, CM & Leonard, RC (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40–44
  Article CAS Google Scholar
• Geisler, JP, Geisler, HE, Wiemann, MC, Givens, SS, Zhou, Z & Miller, GS (1997) Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 66: 435–438
  Article CAS Google Scholar
• Gjerset, RA, Turla, ST, Sobol, RE, Scalise, JT, Mercola, D, Collins, M & Hopkins, PJ (1993) Use of wild type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14: 275–285
  Article Google Scholar
• Hartmann, LC, Podratz, KC, Keeney, GL, Kamel, NA, Edmonson, JH, Grill, JP, Su, JQ, Katzmann, J & Roche, PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64–69
  Article CAS Google Scholar
• Heintz, APM (1996) Surgery in ovarian cancer: the concept of cytoreductive surgery. Curr Opin Obst Gynecol 8: 8–11
  Google Scholar
• Henriksen, R, Strang, P, Wilander, E, Backstrom, T, Tribukait, B & Oberg, K (1994) p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow-cytometry. Gynecol Oncol 53: 301–306
  Article CAS Google Scholar
• Herod, JJO, Eliopoulos, AG, Warwick, J, Niedobitek, G, Kern, DJ & Young, LS (1996) The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184
  CAS PubMed Google Scholar
• Katsaros, D, Levesque, M, Genta, F, Durando, A, Arisio, R, Yu, H, Diamandis, EP & Massobrio, M (1998) Prognostic and predictive value of p53 and waf-1 expression in epithelial ovarian cancer. Proc Am Ass Cancer Res 39: (abstract 1355)
  Google Scholar
• Klemi, PJ, Pylkkanen, L, Kiilholma, P, Kurvinen, K & Joensuu, H (1995) p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201–1208
  Article CAS Google Scholar
• Kohler, MF, Kerns, BM, Humphrey, PA, Marks, JR, Bast, RC & Berchuck, A (1993) Mutation and overexpression of p53 in early stage epithelial ovarian cancer. Obstet Gynecol 81: 643–650
  CAS PubMed Google Scholar
• Kupryjanczyk, J, Bell, DA, Yandell, DW, Scully, RE & Thor, AD (1994) p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102: 671–676
  Article CAS Google Scholar
• Kupryjanczyk, J, Thor, A, Beauchamp, R, Merritt, V, Edgerton, SM, Bell, DA & Yandell, DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961–4965
  Article CAS Google Scholar
• Levesque, MA, Katsarods, D, Yu, H, Zola, P, Sismondi, P, Giardina, G & Diamandis, EP (1995) Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327–1338
  Article CAS Google Scholar
• Mantel, N (1966) Evaluation of survival data and two new rank order statistics arising its consideration. Cancer Chemother Rep 50: 163–170
  CAS Google Scholar
• Marks, JR, Davidoff, AM, Kerns, BJ, Humphrey, PA, Pence, JC, Dodge, RK, Clarke-Pearson, DL, Iglehart, JD, Bast, RC & Berchuck, A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979–2984
  CAS PubMed Google Scholar
• Marx, D, Meden, H, Ziemek, T, Lenthe, T, Kuhn, W & Schauer, A (1998) Expression of the p53 tumour suppressor gene as prognostic marker in platinum treated patients with ovarian cancer. Eur J Cancer 34: 845–850
  Article CAS Google Scholar
• Michieli, P, Chedid, M, Lin, D, Pierce, JM, Mercer, WE & Givol, D (1994) Induction of waf1/cip1 by a p53-independent pathway. Cancer Res 54: 3391–3395
  CAS PubMed Google Scholar
• Momand, J, Zambetti, GP, Olson, DC, Gorge, D & Levine, HJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245
  Article CAS Google Scholar
• Perego, P, Giarola, M, Righetti, SC, Supino, R, Cesarini, C, Delia, D, Pierotti, MA, Miyashita, T, Reed, JC & Zunino, F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556–562
  CAS PubMed Google Scholar
• Potter, ME, Partridge, EE, Hatch, KD, Soong, SJ, Austin, JM & Shingleton, HM (1991) Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 40: 195–200
  Article CAS Google Scholar
• Reles, A, Schmider, A, Press, MF, Schonborn, I, Friedmann, W, Huber-Schumacher, S, Stronmeyer, T & Lintenegger, W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122: 489–494
  Article CAS Google Scholar
• Righetti Della Torre, G, Pilotti, S, Menard, S, Ottone, F, Colnaghi, MI, Pierotti, MA, Lavarino, C, Oriana, S, Cornarotti, M, Bohm, S, Bresciani, GC, Spatti, G & Zunino, F (1996) Comparative study of p53 gene mutations, protein accumulation, and response cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689–693
  CAS PubMed Google Scholar
• Rohlke, P, Milde-Langosch, K, Weyland, C, Pichlmeier, U, Janet, W & Loning, T (1997) p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity. J Cancer Res Clin Oncol 123: 496–501
  Article CAS Google Scholar
• Scambia, G, Benedetti-Panici, P, Ferrandina, G, Distefano, M, Salerno, G, Romanini, ME, Fagotti, A & Mancuso, S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361–366
  Article CAS Google Scholar
• van der Zee, AGJ, Hollema, H, Suurmeijer, AJH, Krans, M, Sluiter, WJ, Willanse, PH, Alders, JG & de-Vries, EF (1995) Value of p-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70–78
  Article CAS Google Scholar
• Werness, BA, Jobe, JS, DiCioccio, A & Pver, S (1997) Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 16: 149–155
  Article CAS Google Scholar
• World Health Organization (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva, pp. 16–21

Download references